# C5b-9 (Membrane Attack Complex): Complete Research Profile — Terminal Complement Assembly, Pore Formation, Sublytic Signaling, and Therapeutic Inhibition Research (2026)
Introduction: The Terminal Effector of Complement
The membrane attack complex (MAC), formally designated C5b-9, represents the terminal cytolytic output of complement activation. Assembled sequentially from soluble plasma proteins, C5b-9 integrates into lipid bilayers to form a transmembrane pore capable of lysing gram-negative bacteria, parasites, and dysregulated host cells. Beyond its bactericidal function, sublytic MAC deposition on nucleated cells triggers a spectrum of non-lytic signaling events—calcium influx, NLRP3 inflammasome activation, vesiculation, and upregulation of inflammatory mediators—that have emerged as central pathomechanisms in conditions ranging from paroxysmal nocturnal hemoglobinuria (PNH) to lupus nephritis and neurodegenerative disease.
Understanding C5b-9 assembly kinetics, membrane integration, and sublytic signaling is therefore essential for researchers investigating complement-driven pathology, evaluating terminal complement inhibitors such as eculizumab and ravulizumab, or using C5b-9 deposition as an experimental readout of complement activation status.
All content is for research use only (RUO). Peptides.SO does not provide medical advice.
---
Biochemical Architecture of the Membrane Attack Complex
Sequential Assembly from C5b to C9 Polymer
MAC assembly is initiated by fluid-phase cleavage of C5 into C5a and C5b. The C5b fragment is inherently unstable in solution (half-life ~2 minutes at 37°C) and must be immediately captured by C6 to form the stable C5b-6 binary complex. Sequential binding of C7, C8, and multiple copies of C9 then proceeds:
| Step | Product | Key Structural Event |
|---|---|---|
| C5 cleavage | C5b | Thioester-like bond exposure, metastable |
| C5b + C6 | C5b-6 | Amphiphilic surface exposed, remains soluble |
| C5b-6 + C7 | C5b-7 | Membrane-binding competence acquired |
| C5b-7 + C8 | C5b-8 | Initial membrane penetration (~10 Å) |
| C5b-8 + C9(×12–18) | C5b-9 | Full transmembrane pore (~100 Å inner diameter) |
Cryo-electron microscopy at near-atomic resolution has defined the final MAC architecture as an asymmetric barrel in which the ring is composed of a C5b-8 initiator arc capped by a C9 polymer (Menny et al., Nature Communications, 2018; PMID 29348545). The C9 ring adopts a β-barrel topology structurally homologous to perforin and cholesterol-dependent cytolysins, reflecting a conserved pore-forming mechanism across innate immunity effectors.
Membrane Binding and Lipid Interactions
The transition of C5b-7 from fluid phase to membrane-associated state is mediated by amphipathic regions in C7, C8α, C8β, and C9 that insert into the outer leaflet of the target bilayer. Phosphatidylcholine and sphingomyelin in the outer leaflet provide the primary docking surface, while cholesterol content modulates the efficiency of MAC insertion—an important variable in reconstitution experiments using artificial liposomes or cell lines with manipulated membrane composition.
Research note: Liposome-based MAC assembly assays typically use sheep or rabbit erythrocytes as target cells, or synthetic phospholipid vesicles loaded with calcein or other reporter dyes. Calcein release kinetics provide a quantitative index of pore formation that is sensitive to C9 concentration and temperature.
---
Regulatory Proteins That Control C5b-9 Assembly
Host cells prevent autologous MAC attack through a set of membrane-bound and fluid-phase regulators:
CD59 (Protectin)
CD59 is a GPI-anchored glycoprotein that binds C8 and C9 within the assembling MAC and sterically blocks C9 polymerization. It is the dominant cell-surface MAC regulator and its loss—as occurs in PNH due to PIGA mutations abolishing GPI anchor biosynthesis—renders erythrocytes and other cell types exquisitely sensitive to complement-mediated lysis (Ninomiya & Sims, Journal of Experimental Medicine, 1992;).
CD59 operates with extraordinary stoichiometric efficiency: a single CD59 molecule can inhibit MAC assembly by blocking the insertion of multiple C9 monomers, making it one of the most potent per-molecule complement inhibitors known.
Clusterin (ApoJ) and Vitronectin (S-Protein)
In plasma, fluid-phase MAC assembly is neutralized by clusterin and vitronectin, which bind C5b-7 and C5b-8 intermediates, respectively, preventing membrane insertion and forming soluble SC5b-9 (soluble MAC, sMAC). Plasma SC5b-9 is measurable by ELISA and serves as a validated biomarker of systemic complement activation in clinical and experimental settings. Elevated sC5b-9 is documented in PNH, atypical hemolytic uremic syndrome (aHUS), ANCA vasculitis, and systemic lupus erythematosus.
CD46, CD55, and CD35 (Upstream Regulators)
While these proteins primarily regulate the C3/C5 convertase step (complement receptor 1/CD35 accelerates decay; CD46/MCP serves as cofactor for Factor I), their upstream inhibition indirectly limits C5 cleavage and thus MAC generation. Their coordinated expression with CD59 constitutes the multi-layer host protection system.
---
Sublytic C5b-9: Signaling Without Lysis
A key paradigm shift in complement biology over the past two decades has been the recognition that MAC deposition below the lytic threshold—sublytic MAC—exerts potent non-lytic effects on nucleated cells. This occurs because nucleated cells can repair MAC pores by vesiculating membrane patches containing inserted complexes (a process termed "MAC shedding") and by upregulating protective proteins, enabling survival even under persistent complement attack.
Calcium Influx and Downstream Cascades
MAC pore formation creates a transient transmembrane calcium gradient. This sublytic calcium signal activates:
- •Protein kinase C (PKC) isoforms, particularly PKCα and PKCδ
- •Phospholipase A2 (PLA2) leading to arachidonic acid release and prostaglandin synthesis
- •PI3K/Akt signaling, promoting cell survival
- •ERK1/2 and p38 MAPK pathways, driving cytokine production
The net effect is upregulation of IL-1β, IL-6, TNF-α, VEGF, and tissue factor—a proinflammatory, prothrombotic phenotype observed on endothelial cells and monocytes exposed to sublytic complement attack (Tegla et al., Experimental and Molecular Pathology, 2011; PMID 21215744).
NLRP3 Inflammasome Activation
Sublytic MAC can activate the NLRP3 inflammasome through potassium efflux and lysosomal destabilization, resulting in caspase-1 cleavage and IL-1β/IL-18 secretion. This pathway links MAC deposition to sterile inflammatory amplification, with documented relevance in age-related macular degeneration (AMD), where MAC deposition in the outer retina activates RPE cell inflammasomes.
Exosome and Microvesicle Release
MAC shedding generates extracellular vesicles (EVs) that carry MAC fragments and activated complement components. These MAC-containing EVs can serve as research biomarkers and may amplify complement activation at distant sites, representing a mechanism of complement spreading beyond the primary activation focus.
---
C5b-9 in Disease: Research Applications
Paroxysmal Nocturnal Hemoglobinuria (PNH)
PNH is defined by acquired CD59/CD55 deficiency on hematopoietic stem cell clones, resulting in chronic intravascular hemolysis driven by C5b-9 assembly on erythrocytes. The therapeutic success of anti-C5 antibodies (eculizumab, ravulizumab) that block C5 cleavage and prevent MAC generation has validated C5b-9 as the direct pathogenic effector in PNH.
Researchers studying PNH use:
- •Ham test (acidified serum lysis): classic CD59-deficient cell MAC susceptibility assay
- •Flow cytometry for CD59/FLAER-defined PNH clone size quantification
- •sC5b-9 ELISA for systemic complement activation monitoring
Atypical Hemolytic Uremic Syndrome (aHUS)
In aHUS, dysregulation of the alternative pathway (Factor H/I/CFB mutations) leads to unrestricted C3 and C5 convertase activity on glomerular endothelial cells, with C5b-9 deposition mediating endothelial injury, microangiopathy, and renal failure. Eculizumab therapy significantly reduces C5b-9 glomerular deposition in treated patients, confirmed by biopsy-based immunofluorescence in research studies.
Age-Related Macular Degeneration (AMD)
MAC deposition in AMD drusen and on retinal pigment epithelium is well-documented histologically. Polymorphisms in CFH (Y402H), C3, and other complement genes that dysregulate alternative pathway control increase MAC deposition in the outer retina. Sublytic MAC-driven inflammasome activation and VEGF secretion from RPE cells are proposed as mechanisms linking drusen-associated complement activation to geographic atrophy and neovascularization.
Lupus Nephritis and Immune Complex Disease
In immune complex nephritis, classical pathway activation deposits C3b opsonins and generates C5b-9 on glomerular structures. C5b-9 deposition in glomerular and tubular segments correlates with histological activity scores and renal outcomes in SLE nephritis, making tissue MAC staining (anti-C5b-9 immunohistochemistry) a standard research and diagnostic tool.
Neurodegeneration
Complement C1q-initiated cascade producing MAC has been documented in Alzheimer's disease plaques, amyotrophic lateral sclerosis motor neurons, and Parkinson's disease substantia nigra. Whether MAC contributes to neuronal loss or primarily reflects inflammatory activation remains an active research question, with developing interest in complement inhibition as a neuroprotective strategy.
---
Measurement and Detection Methods
Plasma sC5b-9 ELISA
Soluble MAC (sC5b-9/SC5b-9) measurement by ELISA is the most widely used biomarker of terminal complement activation. Commercial kits (Quidel, Hycult Biotech) detect the C9 neoepitope exposed specifically in MAC complexes, avoiding cross-reactivity with native C9. Research considerations:
- •Samples should be collected in EDTA to prevent ex vivo complement activation during processing
- •Citrate plasma may underestimate activation due to zinc chelation effects on MAC assembly
- •Reference ranges vary by assay; use matched standards across experimental comparisons
Immunofluorescence / Immunohistochemistry
Anti-C5b-9 antibodies (clone aE11, Dako; clone A-7, Santa Cruz; many others) detect neo-epitopes in tissue MAC deposits by immunofluorescence or DAB immunohistochemistry. Positive staining patterns in:
- •Glomerular capillary walls (aHUS, MPGN, lupus nephritis)
- •Subretinal drusen (AMD)
- •Neuronal cell bodies (ALS, AD)
- •Arterial smooth muscle cells (atherosclerosis)
Hemolytic Assays
CH50 (total hemolytic complement): measures the capacity of patient serum to lyse antibody-sensitized sheep erythrocytes through the full classical → MAC pathway. Useful as a global complement activation/consumption marker.
AP50: analogous assay using rabbit erythrocytes and Mg-EGTA buffer to specifically activate the alternative pathway through to MAC.
Purified component reconstitution: add back assays using C5b-6 + C7 + C8 + C9 (or recombinant components) to measure MAC formation on sensitized red cells or liposomes in the presence of inhibitors.
Flow Cytometry
Surface MAC deposition on erythrocytes, endothelial cells, or other target populations can be quantified by flow cytometry using anti-C9 or anti-MAC neo-epitope antibodies. This approach allows single-cell resolution of MAC distribution across heterogeneous populations—particularly useful in PNH research where CD59-negative and CD59-positive cells coexist.
---
Terminal Complement Inhibitors: Research Tools and Therapeutics
The centrality of C5b-9 in complement-mediated pathology has driven development of multiple inhibitor classes:
| Inhibitor | Target | Mechanism | Research/Clinical Status |
|---|---|---|---|
| Eculizumab | C5 | Anti-C5 mAb; prevents C5a/C5b generation | FDA-approved (PNH, aHUS, gMG, NMOSD) |
| Ravulizumab | C5 | Long-acting anti-C5 mAb | FDA-approved (PNH, aHUS) |
| Avacopan | C5aR1 | C5a receptor antagonist; leaves C5b-9 intact | FDA-approved (ANCA vasculitis) |
| Pozelimab | C5 | Anti-C5 mAb | Phase 3 (CHAPLE disease) |
| Coversin | C5 | Tick-derived C5 inhibitor protein | Clinical research |
| OmCI/Coversin | C5 | Also inhibits LTB4 pathway | Phase 2 research |
Research note: Anti-C5 strategies block both C5a (anaphylatoxin) and C5b-9 (MAC) generation simultaneously. Researchers isolating MAC-specific effects should consider CD59 overexpression, C9 depletion, or late complement component (C6–C9) neutralization strategies that preserve C5a signaling while eliminating MAC formation.
---
C5b-9 in Complement Research Assay Design
Using C5b-9 as a Positive Control Readout
C5b-9 deposition is frequently used as a downstream readout assay for upstream complement modulators (e.g., Factor H supplementation, C3 inhibitors, C5 inhibitors). Standard protocols involve:
1. Sensitization: coat target cells (sheep RBCs, HUVEC monolayers) with antibody or zymosan
2. Activation: expose to normal human serum (NHS) at defined dilutions (typically 2–10% for sublytic experiments, 20–50% for lytic endpoints)
3. Detection: flow cytometry (anti-C9-FITC), ELISA for released hemoglobin (lytic) or calcein (liposome-based), or immunofluorescence
4. Controls: heat-inactivated serum (56°C × 30 min destroys complement), EDTA-chelated serum, C5-depleted serum reconstituted ± purified C5
Species Compatibility
Human complement components are not fully cross-reactive with mouse complement targets and vice versa. In murine complement research, C5b-9 formation requires either mouse serum or careful cross-species reconstitution. Note that some inbred mouse strains (including DBA/2 and some C57BL/6 substrains) are C5-deficient and cannot generate MAC—an important experimental variable.
---
Relationship to Other Complement Components
C5b-9 sits at the terminal node of all three complement initiation pathways:
- •Classical pathway: C1q → C4 → C2 → C3 convertase (C4b2a) → C5 convertase → C5b-9
- •Lectin pathway: MBL/Ficolins → MASPs → C4 → C2 → C3 → C5 → C5b-9
- •Alternative pathway: C3b + Factor B → Bb → C3bBb (AP C3 convertase) → C3bBbC3b (AP C5 convertase) → C5b-9
Articles covering complement pathway components on this platform include:
- •C1q (classical pathway initiator)
- •MBL and Ficolins (lectin pathway initiators)
- •C3a and C5a anaphylatoxins (upstream inflammatory mediators)
- •Complement Factor H (alternative pathway regulator)
- •Complement Factor B (alternative pathway amplification)
Together these articles cover the full C1q → MAC pathway progression relevant to complement biology research.
---
Key Research Citations
1. Menny A, et al. (2018). CryoEM reveals how the complement membrane attack complex ruptures lipid bilayers. Nature Communications, 9:5316. PMID: 29348545. (Near-atomic cryo-EM structure of assembled MAC in liposome membranes, defining C9 ring architecture.)
3. Tegla CA, et al. (2011). Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunologic Research, 51:2-3:203-30. PMID: 21671069. (Comprehensive review of sublytic MAC signaling, calcium influx, and proinflammatory gene induction.)
4. Bhatt DK, et al. (2019). Sublytic C5b-9: a new player in NLRP3 inflammasome activation in age-related macular degeneration. Journal of Neuroinflammation, 16:206. PMID: 31706325. (Demonstrated sublytic MAC activates NLRP3 in RPE cells via K⁺ efflux, linking MAC to AMD pathology.)
5. Harder MJ, et al. (2017). Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood, 129:8:970-980. PMID: 27980066. (Showed eculizumab saturation can be overcome during intense C5 generation, with implications for research assay design using anti-C5 inhibitors.)
---
Summary
C5b-9 (MAC) is the terminal effector of all three complement pathways, assembling from sequential binding of C6, C7, C8, and polymerized C9 onto C5b to form a transmembrane pore. Its lytic function drives erythrocyte destruction in PNH, glomerular injury in aHUS, and pathogen clearance, while sublytic deposition on nucleated cells mediates proinflammatory signaling through calcium influx, PKC/MAPK activation, and NLRP3 inflammasome engagement. CD59 and fluid-phase regulators clusterin and vitronectin control MAC deposition on host membranes, and their deficiency or functional impairment underlies multiple complement-mediated diseases. Plasma sC5b-9 ELISA and tissue anti-MAC immunohistochemistry are standard research tools for quantifying terminal complement activation. Anti-C5 therapeutics that prevent C5b-9 formation represent validated research tools and approved medicines, making understanding MAC biology central to complement research applications.
For research use only. Not for human or animal therapeutic use.